LEXX · Lexaria Bioscience Corp. · Insider Trading
Substantial doubt about the company's ability to continue as a going concern.
“The recurring losses and negative net cash flows raise substantial doubt as to the Company's ability to continue as a going concern. However, we have also concluded that our existing cash, combined with inflows expected from executed license agreements, will not be sufficient to meet the Company's financial obligations for the twelve-month period following the issuance of these consolidated financial statements. Accordingly, there is substantial doubt as to our ability to continue as a going concern within one year from the date of issuance of these financial statements.”View the 10-Q filed Jul 13, 2026
One customer — 100% of revenue (the nine months ended May 31, 2026)
“In the nine months ended May 31, 2026, the Company recognized revenue of $20,000 on a consolidated basis. One customer accounted for 100% of that total.”
2 customers — 100% of revenue (the nine months ended May 31, 2025)
“In the nine months ended May 31, 2025, the Company recognized revenue of $531,923 on a consolidated basis. Two customers accounted for 100% of that total.”
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-03-17 | BUNKA CHRISTOPHER |
Director |
Gift↓
Filing footnotes — common shares (Direct)
The 100,000 shares were gifted back to Lexaria Bioscience Corp. and returned to treasury. |
common shares
|
100,000 |
| 2025-07-30 | BUNKA CHRISTOPHER |
Director |
Buy↑
|
common shares
(I)
|
11,900 |
| 2025-07-29 | Carle Vanessa |
Secretary |
Buy↑
|
common shares
|
750 |
| 2025-07-29 | CHRISTOPHER RICHARD |
Director, Chief Executive Officer |
Buy↑
|
common shares
|
15,000 |
| 2025-07-29 | DOCHERTY JOHN MARTIN |
Director, President & CSO |
Buy↑
|
common shares
|
5,376 |
| 2025-07-29 | BUNKA CHRISTOPHER |
Director |
Buy↑
|
common shares
(I)
|
15,600 |
| 2025-07-29 | McKechnie William Edward |
Director |
Buy↑
|
common shares
|
5,000 |
| 2025-05-15 | DOCHERTY JOHN MARTIN |
Director, President & CSO |
Award↑
|
Stock Options
|
150,000 |
| 2025-05-15 | Bhullar Baljinder |
Director |
Award↑
|
Stock Options
|
11,000 |
| 2025-05-15 | REESE ALBERT L JR |
Director |
Award↑
|
Stock Options
|
11,000 |
| 2025-05-15 | Carle Vanessa |
Secretary |
Award↑
|
Stock Options
|
15,000 |
| 2025-05-15 | Baxter Nicholas W |
Director |
Award↑
|
Stock Options
|
11,000 |
| 2025-05-15 | McKechnie William Edward |
Director |
Award↑
|
Stock Options
|
11,000 |
| 2025-05-15 | Shankman Michael Elliot |
Chief Financial Officer |
Award↑
|
Stock Options
|
50,000 |
| 2025-05-15 | BUNKA CHRISTOPHER |
Director |
Award↑
|
Stock Options
|
11,000 |
| 2025-05-15 | CHRISTOPHER RICHARD |
Director, Chief Executive Officer |
Award↑
|
Stock Options
|
150,000 |
| 2025-01-07 | BUNKA CHRISTOPHER |
Director |
Award↑
Filing footnotes — Restricted Stock Award (Direct)
The closing price on the Issuer's shares on the date of grant was $2.24. Beneficial ownership reflects the aggregate securities held directly. |
Restricted Stock Award
|
100,000 |
| 2024-12-03 | CHRISTOPHER RICHARD |
Director, Chief Executive Officer |
Buy↑
|
common shares
|
27,172 |
| 2024-12-02 | CHRISTOPHER RICHARD |
Director, Chief Executive Officer |
Buy↑
|
common shares
|
22,828 |
| 2024-08-12 | TURKEL CATHERINE C. |
Director |
Buy↑
|
common shares
|
1,600 |
| 2024-07-31 | Carle Vanessa |
Secretary |
Sell↓
|
common shares
|
2,567 |
| 2024-07-26 | TURKEL CATHERINE C. |
Director |
Award↑
|
Stock Options
|
12,000 |
| 2024-07-26 | Baxter Nicholas W |
Director |
Award↑
|
Stock Options
|
12,000 |
| 2024-07-26 | McKechnie William Edward |
Director |
Award↑
|
Stock Options
|
12,000 |
| 2024-07-26 | REESE ALBERT L JR |
Director |
Award↑
|
Stock Options
|
12,000 |
| 2024-05-14 | Carle Vanessa |
Secretary |
Convert↑
|
common shares
|
2,500 |
| 2024-05-14 | Carle Vanessa |
Secretary |
Convert↓
|
Stock Options
|
2,500 |
| 2024-04-26 | Baxter Nicholas W |
Director |
Award↑
|
Stock Options
|
5,000 |
| 2024-04-26 | REESE ALBERT L JR |
Director |
Award↑
|
Stock Options
|
5,000 |
| 2024-04-26 | TURKEL CATHERINE C. |
Director |
Award↑
|
Stock Options
|
5,000 |
| 2024-04-26 | BUNKA CHRISTOPHER |
Director |
Award↑
|
Stock Options
|
49,500 |
| 2024-04-26 | McKechnie William Edward |
Director |
Award↑
|
Stock Options
|
5,000 |
| 2024-04-26 | Carle Vanessa |
Secretary |
Award↑
|
Stock Options
|
10,000 |
| 2024-04-26 | DOCHERTY JOHN MARTIN |
Director, President & CSO |
Award↑
|
Stock Options
|
49,500 |
| 2023-10-26 | DOCHERTY JOHN MARTIN |
Director, President & CSO |
Award↑
|
Stock Options
|
30,000 |
| 2023-10-26 | Carle Vanessa |
Secretary |
Award↑
|
Stock Options
|
12,500 |
| 2023-10-26 | BUNKA CHRISTOPHER |
Director |
Award↑
|
Stock Options
|
30,000 |
| 2023-07-25 | TURKEL CATHERINE C. |
Director |
Award↑
|
Stock Options
|
5,000 |
| 2023-07-25 | REESE ALBERT L JR |
Director |
Award↑
|
Stock Options
|
5,000 |
| 2023-07-25 | Baxter Nicholas W |
Director |
Award↑
|
Stock Options
|
5,000 |
| 2023-07-25 | McKechnie William Edward |
Director |
Award↑
|
Stock Options
|
5,000 |
| 2023-02-09 | TURKEL CATHERINE C. |
Director |
Buy↑
|
Common Shares
|
1,500 |
| 2022-10-14 | Downey Gregory |
Chief Financial Officer |
Buy↑
Filing footnotes — common shares (Direct)
This Form 4A is being filed to correct the transaction code for the open market purchase made by Mr. Downey as originally notated as a grant or award in the Form 4 filed on October 18, 2022. |
common shares
|
121 |
| 2022-10-13 | BUNKA CHRISTOPHER |
Director |
Buy↑
Filing footnotes — common shares (Indirect)
This Form 4/A is being filed to correct the transaction code for the open market purchase of common shares made by Mr. Bunka as previously notated as a grant or award in the Form 4 originally filed on 10/13/2022. |
common shares
(I)
|
16,600 |
| 2022-10-12 | McKechnie William Edward |
Director |
Award↑
|
Stock Options
|
18,200 |
| 2022-10-12 | TURKEL CATHERINE C. |
Director |
Award↑
|
Stock Options
|
1,600 |
| 2022-10-12 | BUNKA CHRISTOPHER |
Director |
Buy↑
Filing footnotes — common shares (Indirect)
This Form 4/A is being filed to correct the transaction code for the open market purchase of common shares made by Mr. Bunka as previously notated as a grant or award in the Form 4 originally filed on 10/13/2022. |
common shares
(I)
|
21,900 |
| 2022-10-12 | REESE ALBERT L JR |
Director |
Award↑
|
Stock Options
|
3,200 |
| 2022-10-12 | Baxter Nicholas W |
Director |
Award↑
|
Stock Options
|
18,200 |
| 2022-09-02 | TURKEL CATHERINE C. |
Director |
Award↑
|
Stock Options
|
3,400 |